- Home
- COGT vs SABR Comparison
COGT vs SABR Comparison
Compare COGT & SABR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COGT
- SABR
- Stock Information
- Founded
- COGT 2014
- SABR 2006
- Country
- COGT United States
- SABR United States
- Employees
- COGT 205
- SABR N/A
- Industry
- COGT Biotechnology: Pharmaceutical Preparations
- SABR Computer Software: Programming Data Processing
- Sector
- COGT Health Care
- SABR Technology
- Exchange
- COGT Nasdaq
- SABR Nasdaq
- Market Cap
- COGT 822.0M
- SABR 981.2M
- IPO Year
- COGT 2018
- SABR 2014
- Fundamental
- Price
- COGT $7.23
- SABR $2.63
- Analyst Decision
- COGT Buy
- SABR Hold
- Analyst Count
- COGT 6
- SABR 5
- Target Price
- COGT $15.20
- SABR $4.12
- AVG Volume (30 Days)
- COGT 2.1M
- SABR 5.4M
- Earning Date
- COGT 08-05-2025
- SABR 07-31-2025
- Dividend Yield
- COGT N/A
- SABR N/A
- EPS Growth
- COGT N/A
- SABR N/A
- EPS
- COGT N/A
- SABR N/A
- Revenue
- COGT N/A
- SABR $3,023,296,000.00
- Revenue This Year
- COGT N/A
- SABR $2.85
- Revenue Next Year
- COGT N/A
- SABR $3.47
- P/E Ratio
- COGT N/A
- SABR N/A
- Revenue Growth
- COGT N/A
- SABR 2.56
- 52 Week Low
- COGT $3.72
- SABR $1.93
- 52 Week High
- COGT $12.61
- SABR $4.63
- Technical
- Relative Strength Index (RSI)
- COGT 65.40
- SABR 46.92
- Support Level
- COGT $6.88
- SABR $2.57
- Resistance Level
- COGT $7.83
- SABR $3.03
- Average True Range (ATR)
- COGT 0.56
- SABR 0.14
- MACD
- COGT 0.09
- SABR -0.02
- Stochastic Oscillator
- COGT 78.17
- SABR 29.20
About COGT Cogent Biosciences Inc.
Cogent Biosciences Inc a biotechnology company focused on developing precision therapies for genetically defined diseases. It designs rational precision therapies that treat the underlying cause of disease and improve the lives of patients. Its program CGT9486, is a selective tyrosine kinase inhibitor designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. In the vast majority of cases, KIT D816V is responsible for driving Systemic Mastocytosis (SM), a serious disease caused by the unchecked proliferation of mast cells. Exon 17 mutations are also found in patients with advanced gastrointestinal stromal tumors (GIST), a type of cancer with dependence on oncogenic KIT signaling.
About SABR Sabre Corporation
Sabre holds the number-two air booking volume share in the global distribution system industry. The travel solutions segment represented 91% of total 2024 revenue, split between distribution (79% of segment sales) and airline IT solutions (21%) revenue. The company also has a growing hotel IT solutions division (9% of revenue). Transaction fees, which are mostly tied to volume and not price, account for the bulk of sales and profits.